MGTX
HealthcareMeiraGTx Holdings plc
$7.55
$-0.26 (-3.33%)
Jan 5, 2026
Price History (1Y)
Analysis
MeiraGTx Holdings plc is a biotechnology company listed in the healthcare sector. With a market capitalization of $607.71M and 409 employees, it operates within the industry of biotechnology. The company's financial health appears to be challenging. Net income (TTM) stands at -$168,688,000, indicating significant losses. EBITDA is also negative at -$151,432,000, further highlighting operational difficulties. The operating margin is -11232.0%, suggesting substantial costs outweigh revenue. Meanwhile, the gross margin is 41.0%, which indicates some level of efficiency in production or sales. On the balance sheet side, cash stands at $14.84M, while debt totals $88.06M, resulting in a current ratio of 0.22. The valuation context shows mixed indicators. The forward P/E ratio is -3.01, and the price to book value is -14.98. This may suggest that investors are anticipating significant future losses or a potential restructuring. On the other hand, revenue (TTM) stands at $27.42M, albeit with a significant decline of -96.2% year-over-year. Dividend data is not available, and the payout ratio is 0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Visit website →Key Statistics
- Market Cap
- $607.71M
- P/E Ratio
- N/A
- 52-Week High
- $9.73
- 52-Week Low
- $4.55
- Avg Volume
- 535.38K
- Beta
- 1.39
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 409